Swissinfo published a feature story highlighting the need for Switzerland to enact incentives that will attract private investment into antibiotic R&D and ensure that patients in the country have access to advanced antibiotics. As one physician working in a burn unit in Zurich noted, while AMR is relatively low in Switzerland, the lack of advanced antibiotics licensed in the country puts patients at risk and means that lifesaving medicines need to be imported on a case-by-case basis.
AMR Action Fund CEO Henry Skinner added, “This is a global problem. High-income countries like Switzerland really need to step up and provide the right market incentives, so there’s enough return on investment to have companies, small and big, continue developing antibiotics… If selling antibiotics loses money, no one will invest.”
Read the full article here.